Multicentre trials: a US regulatory perspective

DOI10.1191/0962280205SM398OAMaRDI QIDQ5442642zbMATH OpenOpenAlexWikidataFDO

Authors Charles Anello, R. T. O'Neill, S. D. Dubey

Publication date 22 February 2008

Published in Statistical Methods in Medical Research (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1191/0962280205sm398oa

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Recommendations

• Multicentre trials: a US regulatory perspective
• Bayesian analysis of multicentre trial outcomes
• Bayesian analysis of multicentre trial outcomes
• Statistical issues in the drug evaluation process: some issues in applying the ICH guidelines
• A Regulatory View on Adaptive/Flexible Clinical Trial Design

Cites work

• Probability Models And Computational Models For Anova In Multicenter Clinical Trials
• Testing for Qualitative Interactions between Treatment Effects and Patient Subsets
• Understanding on the pooled test for controlled clinical trials

Cited in

(4)

• Supporting information blinded sample size recalculation in multicentre trials with normally distributed outcome
• The changing landscape of data monitoring committees. Perspectives from regulators, members, and sponsors
• Multicentre trials: a US regulatory perspective
• Statistical issues in the drug evaluation process: some issues in applying the ICH guidelines

This page was built for publication: Multicentre trials: a US regulatory perspective

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5442642)